Replies to post #257 on Ionis Pharmaceuticals Inc (IONS)

[surf1944]

1:31AM ISIS Pharm reports Phase 2 data on ISIS-APOCIII Rx showing significant reductions in triglycerides and APOC-III in patients with high triglycerides and Type 2 diabetes (ISIS) 21.99 : Co reports that data from the Phase 2 study of ISIS-APOCIIIRx in patients with high triglycerides and type 2 diabetes. In this study, patients treated with ISIS-APOCIIIRx experienced an 88 percent reduction in apolipoprotein C-III, a 72% reduction in triglyceride levels, a 40 percent increase in high-density lipoprotein cholesterol, the 'good' cholesterol, and improvements in other atherogenic lipid parameters. In addition, patients dosed with ISIS-APOCIIIRx showed consistent trends toward enhanced insulin sensitivity with improvements in multiple measures of glucose control. Isis is also evaluating ISIS-APOCIIIRx in a separate Phase 2 study in patients with moderate to severe high triglycerides and plans to report data from this study this summer.